Immunic (IMUX) Trade: Fresh Capital Re-Prices Risk — Target $15 on Mid-Term Recovery
Immunic’s equity looks to have stabilized after a reported $200 million private placement that materially lengthens runway. With a market cap of roughly $158.6M, bullish technicals (RSI ~56, MACD positive) and compressed downside vs. the 52-week high of $15.10, this is a mid-term (45 trading days) trade to capture a recovery toward the prior range.…